Article Figures & Tables
Tables
- Table 1: Sociodemographic and health characteristics and prevalence of cost-related nonadherence among respondents to the Canadian Community Health Survey, January-June 2016
Variable No. of respondents Weighted proportion of total population (95% CI) Weighted proportion with cost-related nonadherence (95% CI) Overall 28 091 - 5.53 (5.06-6.00) Sex Female 15 024 50.66 (50.66-50.66) 6.50 (5.81-7.19) Male 13 067 49.34 (49.34-49.34) 4.54 (3.92-5.16) Age, yr 12-17 2511 8.69 (8.43-8.95) 2.06 (1.32-2.80) 18-34 5234 25.21 (24.96-25.47) 7.65 (6.47-8.82) 35-44 3568 14.70 (14.20-15.20) 6.04 (4.77-7.31) 45-54 4046 16.79 (16.08-17.51) 5.64 (4.51-6.76) 55-64 4897 16.13 (15.63-16.64) 5.01 (4.00-6.01) 65-74 4615 11.49 (11.17-11.80) 4.77 (3.80-5.74) ≥ 75 3220 6.98 (6.67-7.30) 3.35 (2.35-4.36) Self-reported health status Excellent 5996 23.99 (23.13-24.86) 2.88 (2.10-3.66) Very good 10 221 37.32 (36.41-38.23) 3.64 (3.07-4.22) Good 8016 27.39 (26.51-28.28) 6.90 (5.92-7.88) Fair 2777 8.04 (7.54-8.54) 12.54 (10.21-14.87) Poor 1036 3.11 (2.78-3.45) 18.42 (14.56-22.28) No. of chronic conditions 0 12 339 50.54 (49.61-51.46) 3.18 (2.67-3.69) 1 7401 26.05 (25.20-26.89) 6.01 (5.09-6.93) 2 4380 12.83 (12.24-13.42) 7.32 (5.96-8.67) 3 2328 6.24 (5.86-6.63) 12.43 (9.89-14.97) ≥ 4 1643 4.34 (3.98-4.70) 14.82 (12.31-17.34) Ethnic background South Asian 549 4.41 (3.89-4.93) 6.60 (3.01-10.18) East Asian 671 4.33 (3.84-4.83) 3.83 (2.22-5.43) Aboriginal 1349 3.61 (3.27-3.95) 10.94 (7.95-13.92) White 23 029 72.25 (71.30-73.21) 5.13 (4.66-5.61) Other 2493 15.39 (14.58-16.21) 6.30 (4.76-7.84) Total household income, $ < 20 000 2675 7.11 (6.62-7.60) 11.14 (8.85-13.43) 20 000-39 999 4940 13.76 (13.13-14.39) 9.44 (7.92-10.95) 40 000-59 999 4469 14.03 (13.40-14.66) 7.03 (5.74-8.32) 60 000-79 999 3631 12.93 (12.27-13.60) 5.56 (4.27-6.84) 80 000-99 999 3056 11.52 (10.90-12.14) 4.81 (3.48-6.15) 100 000-149 999 4905 19.87 (19.07-20.68) 3.57 (2.69-4.45) ≥ 150 000 4415 20.78 (19.94-21.62) 2.27 (1.59-2.94) Education Secondary school 6234 22.67 (21.83-23.52) 6.69 (5.59-7.8) Postsecondary 15 001 56.66 (55.70-57.61) 5.19 (4.57-5.82) Less than secondary school 6464 19.02 (18.40-19.64) 5.11 (4.17-6.05) Prescription drug insurance Employer plan 13 573 51.58 (50.60-52.55) 3.44 (2.92-3.96) Association plan 2418 7.93 (7.41-8.45) 3.86 (2.65-5.07) Government plan 5896 16.56 (15.90-17.23) 7.13 (6.09-8.18) None 5331 19.46 (18.65-20.26) 11.29 (9.69-12.88) No. of prescription drugs in prior 12 mo 0 9108 36.48 (35.57-37.40) 0.88 (0.63-1.13) 1 or 2 8212 30.70 (29.78-31.63) 6.96 (6.01-7.92) 3 or 4 5195 16.11 (15.44-16.79) 8.47 (7.29-9.65) ≥ 5 4976 13.54 (12.98-14.09) 12.00 (10.23-13.76) Out-of-pocket prescription drug spending in prior 12 mo, $ 0 12 133 47.34 (46.37-48.31) 1.68 (1.35-2.01) 1-200 8725 30.06 (29.20-30.92) 6.30 (5.42-7.19) 201-500 3185 9.56 (9.04-10.08) 13.50 (11.10-15.90) 501-1000 1722 4.79 (4.44-5.14) 15.37 (12.31-18.43) > 1000 1149 3.19 (2.88-3.50) 17.96 (14.34-21.58) Province British Columbia 3757 13.25 (13.25-13.25) 8.11 (6.74-9.47) Alberta 3476 11.53 (11.53-11.53) 5.73 (4.55-6.91) Saskatchewan 1187 2.95 (2.95-2.95) 5.69 (3.38-8.01) Manitoba 1356 3.39 (3.39-3.39) 5.51 (3.75-7.27) Ontario 8733 39.00 (39.00-39.00) 5.77 (4.85-6.68) Quebec 6160 23.18 (23.18-23.18) 3.70 (3.01-4.39) New Brunswick 900 2.11 (2.11-2.11) 4.83 (3.05-6.60) Nova Scotia 1237 2.66 (2.66-2.66) 5.22 (3.55-6.89) Prince Edward Island 449 0.41 (0.41-0.41) 6.08 (3.66-8.51) Newfoundland and Labrador 836 1.50 (1.50-1.50) 4.51 (2.68-6.34) Note: CI = confidence interval.
- Table 2: Types of drugs foregone and cost of prescriptions foregone owing to cost-related nonadherence
Variable Weighted total (95% CI) Weighted proportion
of population with cost-related nonadherence (95% CI)Condition treated by drugs foregone in prior 12 mo Depression, anxiety or other mental health condition 331 866 (268 881-394 851) 21.43 (17.99-24.87) Arthritis or chronic pain 252 590 (190 989-314 192) 16.31 (12.68-19.76) Heart disease, cholesterolemia or high blood pressure 244 306 (191 779-296 833) 15.78 (12.60-18.95) Infection 227 983 (166 112-289 855) 14.72 (11.16-18.28) Gut problems (e.g., peptic ulcer, heartburn, bowel disease) 175 502 (136 984-214 020) 11.33 (8.96-13.71) Asthma or chronic obstructive pulmonary disease 152 800 (119 051-186 548) 9.87 (7.78-11.95) Diabetes 127 437 (93 474-161 399) 8.23 (6.13-10.33) Cancer 9267 (4604-12 931) 0.60 (0.29-0.90) Other 658 065 (573 155-742 975) 42.49 (38.56-46.42) Cost of most recent foregone prescription, $ 1-25 164 219 (120 569-207 868) 11.31 (8.54-14.08) 26-50 263 747 (214 091-313 403) 18.16 (15.20-21.13) 51-200 749 933 (650 338-849 528) 51.65 (47.18-56.12) 201-1000 236 765 (181 154-292 376) 16.31 (12.75-19.86) > 1000 37 326 (24 227-50 426) 2.57 (1.69-3.45) Note: CI = confidence interval.
Service Weighted total (95% CI) Weighted proportion of total population (95% CI) Weighted proportion of population with cost-related nonadherence (95% CI) Physician visit 303 341 (242 651-364 032) 0.99 (0.79-1.19) 19.50 (16.11-22.89) Emergency department 93 295 (63 451-123 139) 0.31 (0.21-0.40) 6.00 (4.18-7.82) Hospital stay 26 423 (14 502-38 345) 0.09 (0.05-0.13) 1.70 (0.94-2.46) Any of the above 374 461 (308 263-440 659) 1.23 (1.01-1.44) 24.08 (20.56-27.59) Note: CI = confidence interval.
- Table 4: Expenditure areas in which trade-offs were made in order to afford prescription drugs
Area Weighted total (95% CI) Weighted proportion of total population (95% CI) Leisure or vacation 836 885 (735 937-937 832) 2.74 (2.41-3.07) Food 729 706 (637 166-822 246) 2.39 (2.08-2.69) Car, public transit or other transportation costs 375 774 (307 488-444 060) 1.23 (1.01-1.45) Other health care expenses for self or anyone else in household 238 611 (180 067-297 155) 0.78 (0.59-0.97) Heat 238 178 (182 771-293 584) 0.78 (0.60-0.96) Housing 206 056 (147 832-265 289) 0.67 (0.48-0.86) Other expenses not already mentioned 297 882 (231 905-363 858) 0.97 (0.76-1.19) Any of the above 1 447 183 (1 313 582-1 580 785) 4.73 (4.30-5.17) Note: CI = confidence interval.
In this issue
Article tools
Respond to this article
Related Articles
Cited By...
- Effect of universal no-cost coverage on use of long-acting reversible contraception and all prescription contraception: population based, controlled, interrupted time series analysis
- From Patient Voices to Policy: Data Analytics Reveals Patterns in Ontarios Hospital Feedback
- Predictors of cost-related medication nonadherence in Canada: a repeated cross-sectional analysis of the Canadian Community Health Survey
- Les defis du cout de la vie soulignent lurgence pour les medecins de prescrire des medicaments abordables
- Cost-of-living challenges highlight urgency for clinicians to prescribe affordable medications
- Biologic DMARD Access and Medication Cost-related Nonadherence in Rheumatology Patients in Canada: A Cross-sectional Survey
- Canadian Rheumatology Association Living Guidelines for the Pharmacological Management of Rheumatoid Arthritis With Disease-Modifying Antirheumatic Drugs
- Acceptability of a short list of essential medicines to patients and prescribers: Multimethod study
- Introduction of publicly funded pharmacare and socioeconomic disparities in glycemic management in children and youth with type 1 diabetes in Ontario, Canada: a population-based trend analysis
- Inciter les medecins a prescrire en se souciant davantage des couts: Strategie de changement
- Engaging physicians to prescribe more cost-effectively: Blueprint for change
- Drug coverage in Canada: gaps and opportunities